Shares of Gerresheimer AG slid another 5.4% to €26.74 on May 13, extending a brutal decline for the German pharmaceutical packaging company now engulfed by an accounting scandal, serial profit warnings, and a balance sheet crisis. For investors, the question is no longer about growth — it's about survival.
An Accounting Probe Gutted Whatever Trust Was Left
Gerresheimer warned that an expanded accounting review would weigh on its 2025 results and cut its outlook, including lowering its margin forecast and projecting a sharp drop in earnings.
Investigators found that individual employees violated internal guidelines and accounting regulations, with corrections touching revenue recognition and inventory valuation across both 2024 and 2025. Following several profit warnings, the share price collapse, and the BaFin proceedings, long-time CEO Dietmar Siemssen left the company, and the CFO had already departed. The leadership vacuum makes it nearly impossible for outsiders to gauge what the real numbers are.
The Debt Load Leaves Almost No Room for Error
The Bormioli acquisition pushed Gerresheimer's net debt-to-EBITDA leverage ratio to 4.15x, just below its previous 4.25x debt covenant.
The company now carries a debt-to-equity ratio of 164.82 with a current ratio of just 0.98. To buy time, 96% of €870 million in promissory note holders agreed to extend the audit deadline to September 30, 2026, and key debt covenants were waived through Q3 2026. Creditor patience is finite — if the delayed annual report due in June reveals further surprises, refinancing risk becomes existential.
Selling the Crown Jewels to Stay Afloat
Morgan Stanley is managing the sale of U.S. subsidiary Centor Inc., acquired eleven years ago for $725 million.
With a book value of €292 million, Centor is considered the group's most profitable segment; its sale is a strategic necessity to reduce net financial debt of approximately €1.2 billion. Parting with your best asset to service debt rarely signals a turnaround — it signals distress.
Analysts Have Turned Decisively Bearish
Barclays slashed its price target to €19 and downgraded to "Underweight," while UBS downgraded Gerresheimer to Sell from Neutral in February. JPMorgan's analyst described the trajectory as "from bad to worse to even worse."
Since peaking in September 2023, shares have plummeted roughly 80%. With the audited 2025 financials still pending and the Centor sale incomplete, the stock remains a bet on management execution at a company where execution has been the core problem.